NT-501 is under clinical development by Neurotech Pharmaceuticals and currently in Phase II for Glaucoma. According to GlobalData, Phase II drugs for Glaucoma have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NT-501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NT-501 is under development for the treatment of glaucoma and macular telangiectasia type 2 (Mactel). NT-501 is an intraocular implant. NT-501 consists of encapsulated human cells genetically modified (designated as NTC-201) to secrete ciliary neurotrophic factor (CNTF), designed to continually deliver a low, safe and therapeutic dose of CNTF into the back of the eye.
It was also under development for the treatment of geographic atrophy associated with dry atropic macular degeneration, ischemic optic neuropathy, achromatopsia, amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, spinal muscular atrophies, retinitis pigmentosa, choroideremia and usher syndrome type-2 and type-3.
Neurotech Pharmaceuticals overview
Neurotech Pharmaceuticals (Neurotech), a subsidiary of Neurotech Holdings LLC, is a developer of transformative therapies. The company offers ECT Platform, ECT Pipeline and NT-501 ECT. Its ECT is a drug delivery platform in development for the treatment of a broad array of eye diseases. Neurotech’s ECT pipeline products include NT-501 CNTF and NT-503 Anti –VEGF. The company offers mactel, glaucoma and wet AMD. Its ECT systems produce biotherapeutic drug classes including peptides, hormones and monoclonal antibodies. The company’s ECT platform includes therapies for the treatment of macular telangiectasia and glaucoma, and combination therapies for retinal degenerative disorders Neurotech is headquartered in Cumberland, Rhode Island, the US.
For a complete picture of NT-501’s drug-specific PTSR and LoA scores, buy the report here.